A Phase 2 interventional study of vancomycin hydrochloride and tobramycin sulfate in Prosthetic Joint Infection, sponsored by Osteal Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Osteal Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study Type
Prospective, single-arm, open-label, multicenter (3 to 5 sites), interventional trial.
Primary Study Objective
The objective of the study is to determine the safety profile of local antibiotic irrigation for the treatment of PJI.
Primary Outcome Measure
The overall safety profile is characterized by assessing the incidence of adverse events (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and unexpected adverse reactions.
Follow-up
Patients will be assessed for all measures at 3 weeks, 6 weeks, 12 weeks, and 12 months from initial surgery.
Osteal Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Joint irrigation with vancomycin and tobramycin
Combination Product: vancomycin hydrochloride and tobramycin sulfate
Drug pages: Vancomycin · Tobramycin
vancomycin hydrochloride and tobramycin sulfate via local irrigation
Safety Evaluations: Number and Frequency of Adverse Events Among Participants
The overall safety profile is characterized by assessing the incidence of adverse events (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and unexpected adverse reactions.
Time frame: 12 months
| Milestone | Local Irrigation With Vancomycin + Tobramycin |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
The overall safety profile is characterized by assessing the incidence of adverse events (AEs), serious adverse events (SAEs), suspected adverse reactions, adverse reactions, and unexpected adverse reactions.
| Participants | Experimental |
|---|---|
| Any Adverse Event | 14 |
| AE Relationship to NPWT Device UNRELATED | 14 |
| AE Relationship to Study Medication UNRELATED | 14 |
| AE Relationship to Study Treatment Procedure UNRELATED | 14 |
| Severity - Mild | 14 |
| Severity - Moderate | 7 |
| Severity - Severe | 6 |
| Serious Adverse Event | 7 |
| SAE Relationship to NPWT Device UNRELATED | 7 |
| SAE Relationship to Study Medication UNRELATED | 7 |
| SAE Relationship to Study Treatment Procedure UNRELATED | 7 |
| Suspected Adverse Reaction | 0 |
| Adverse Reactions | 0 |
Collected over 12 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Local Irrigation With Vancomycin + Tobramycin | 0/15 (0%) | 7/15 (46.7%) | 14/15 (93.3%) |
| Event | Local Irrigation With Vancomycin + Tobramycin |
|---|---|
| Chest painCardiac disorders | 2/15 |
| Atrial FlutterCardiac disorders | 1/15 |
| Cardiac failure congestiveCardiac disorders | 1/15 |
| Pulmonary oedemaCardiac disorders | 1/15 |
| Dental cariesGastrointestinal disorders | 1/15 |
| PneumoniaInfections and infestations | 1/15 |
| Rotavirus infectionInfections and infestations | 1/15 |
| SepsisInfections and infestations | 1/15 |
| Avulsion fractureInjury, poisoning and procedural complications | 1/15 |
| FallInjury, poisoning and procedural complications | 1/15 |
| Event | Local Irrigation With Vancomycin + Tobramycin |
|---|---|
| Anaemia postoperativeInjury, poisoning and procedural complications | 8/15 |
| Peripheral swellingGeneral disorders | 5/15 |
| HypotensionVascular disorders | 4/15 |
| PyrexiaGeneral disorders | 2/15 |
| CystitisInfections and infestations | 2/15 |
| PneumoniaInfections and infestations | 2/15 |
| FallInjury, poisoning and procedural complications | 2/15 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/15 |
| Back painMusculoskeletal and connective tissue disorders | 2/15 |
| Urinary retentionRenal and urinary disorders | 2/15 |
| Age, Continuous(Years) | Experimental |
|---|---|
| Mean | 69.27 ± 7.329 |
| Age, Customized(Participants) | Experimental |
|---|---|
| <60 years | 2 |
| >= 60 years | 13 |
| Sex: Female, Male(Participants) | Experimental |
|---|---|
| Female | 9 |
| Male | 6 |
| Race/Ethnicity, Customized(Participants) | Experimental |
|---|---|
| Black or African American | 1 |
| White | 14 |
| Region of Enrollment(participants) | Experimental |
|---|---|
| United States | 15 |
| Affected Joint(Participants) | Experimental |
|---|---|
| Knee | 14 |
| Hip | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Aug 2020, 21 months.
Results were first posted in Dec 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vancomycin · Tobramycin
Osteal Therapeutics, Inc.